LY 171883

Subscribe to Selected New Research on LY 171883

35 relevant articles (2 outcomes, 3 trials/studies) found for this Bio-Agent

Description: structure in first source; leukotriene receptor antagonist

Also Known As:

1-((2-hydroxy-3-propyl)-4-(1H-tetrazol-5-yl)butoxyphenyl)ethanone; LY-171883; LY171883; Lilly 171883; Ethanone, 1-(2-hydroxy-3-propyl-4-(4-(1H-tetrazol-5-yl)butoxy)phenyl)-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Ketones: 289

Acetophenones: 8

LY 171883: 35

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Tetrazoles: 5

LY 171883: 35

Related Diseases

1.	Weight Gain 11/01/1990 - "Posttreatment with 5,8,11,14-eicosatetraynoic acid (ETYA), a nonmetabolized competitive inhibitor of arachidonic acid metabolism, or the leukotriene receptor blockers, FPL 55712 and LY 171883, also dramatically reduced the lung weight gain caused by phosgene" Get all the results and reference details, order at left...
2.	Hyperinsulinism (Hyperinsulinemia) 10/01/1989 - "In characterizing this putative central mechanism for the regulation of pancreatic insulin secretion, hyperinsulinemia and fever elicited by IL-1 injected intravenously (iv) or intracerebroventricularly (icv) was totally eliminated by prior cyclooxygenase inhibition with indomethacin, ibuprofen, or meclofenamate but not lipoxygenase inhibition with propyl gallate or leukotriene receptor antagonism with LY 171883" Get all the results and reference details, order at left...
3.	Fever (Fevers) 10/01/1989 - "In characterizing this putative central mechanism for the regulation of pancreatic insulin secretion, hyperinsulinemia and fever elicited by IL-1 injected intravenously (iv) or intracerebroventricularly (icv) was totally eliminated by prior cyclooxygenase inhibition with indomethacin, ibuprofen, or meclofenamate but not lipoxygenase inhibition with propyl gallate or leukotriene receptor antagonism with LY 171883" Get all the results and reference details, order at left...
4.	Septic Shock (Toxic Shock Syndrome) 07/01/1990 - "LY171883 preserves mesenteric perfusion in porcine endotoxic shock." 11/01/1990 - "In the present study, the effects of a selective LTD4/E4 receptor antagonist, LY171883 (LY), or a selective LTD4 receptor antagonist, SKF-104353 (SKF), were assessed on splanchnic and pulmonary localization of 99mTechnetium-labeled human serum albumin (99mTc-HSA) in acute endotoxic shock in the rat" Get all the results and reference details, order at left...
5.	Shock 02/01/1995 - "Circulatory shock was induced by acute hemorrhage to a mean arterial pressure (MAP) of 45 mm Hg. We investigated the effect of SQ-29,548 and LY-171883 on the progression of circulatory shock" 01/01/1987 - "In this study the effect of LY171883, a selective leukotriene D4/E4 antagonist, on the hemodynamic alterations of endotoxin shock was assessed" Get all the results and reference details, order at left...
31 Diseases and 35 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Leukotriene Receptors (Leukotriene Receptor)
2.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
3.	Indomethacin (Indometacin)
4.	Lipoxygenase (Lipoxygenase-1)
5.	Arachidonic Acid (Vitamin F)
6.	5,8,11,14-Eicosatetraynoic Acid (5,8,11,14 Eicosatetraynoic Acid)
7.	Propyl Gallate
8.	Phosgene
9.	Meclofenamic Acid (Meclofenamate)
10.	Interleukin-1 (Interleukin 1)
35 Drugs and Important Bio-Agents and 23 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Fat-Restricted Diet (Diet, Fat Restricted)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>